Date | Price Target | Rating | Analyst |
---|---|---|---|
5/17/2024 | $14.00 | Outperform | Oppenheimer |
1/5/2024 | $8.00 | Overweight | Cantor Fitzgerald |
10/26/2022 | $15.00 | Buy | Ladenburg Thalmann |
1/31/2022 | $14.00 → $18.00 | Buy | HC Wainwright & Co. |
10/11/2021 | $9.00 → $14.00 | Buy | HC Wainwright & Co. |
Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.83, a high estimate of $40.00, and a low estimate of $8.00. A negative
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40 price target.
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024.
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company. "It is a pleasure to welcome Philip to our Board of Directo
-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue- -Upfront Payment and Investment Extends Cash Runway into 2026- -Potential Milestones from Combined Distribution Agreements Now Total approximately $1.5 Billion- -Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel- SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences. Event:H.C. Wainwright 26th Annual Global Investment Conference (New York, NY)Presentation:September 9, 2024 at 2:00 p.m. ETFormat:Company presentation and one-on-one meetings Event:6th Annual Exosome-Based Therapeutic Summit (Boston, MA)Presentation:September 17-19, 2024Format:Company presentation and industry panel Event:2024 Cantor Fitzgerald's Global Healthcare Conferen
-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On Track to Report Top-Line Data from Cohort A in Q4 2024- -Reported Positive 3-Year Skeletal and Cardiac Data from HOPE-2 Open-Label Extension Trial- -Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the second quarter ended June 3
3 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On Track to Report Top-Line Data from Cohort A in Q4 2024- -Reported Positive 3-Year Skeletal and Cardiac Data from HOPE-2 Open-Label Extension Trial- -Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the second quarter ended June 3
-Company to Host Conference Call, August 7, 2024 at 4:30 p.m. ET- SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the second quarter ended June 30, 2024, after the market close on Wednesday, August 7, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on August 7. Title:Capricor Therapeutics Second Quarter 2024 Financial Results and Recent Corporate Update Conference Call and Webcast Date:Wednesday, August 7, 2024 Time:4:30 p.m. ET Conference Call Details:Toll-Free:
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA– –Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1– –Recent FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission at Upcoming Type-B Clinical FDA Meeting in May 2024– –Plan to Report 3-Year Data from HOPE-2 Open-Label Extension (OLE) Trial in Q2 2024– –Conference Call
Oppenheimer initiated coverage of Capricor Therapeutics with a rating of Outperform and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $8.00
Ladenburg Thalmann initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $15.00
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)